DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 USDMF

1 API Suppliers
1 USDMF

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 149882-10-0, Osi-211, Lurtotecan [inn], 4j1l80t08i, Gg-211, Nx-211

Molecular Formula

C₂₈H₃₀N₄O₆

Molecular Weight

518.6 g/mol

InChI Key

RVFGKBWWUQOIOU-NDEPHWFRSA-N

FDA UNII

4J1L80T08I

Lurtotecan is a semisynthetic analogue of camptothecin with antineoplastic activity. Lurtotecan selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. Independent from DNA replication inhibition, lurtotecan also inhibits RNA synthesis, multi-ubiquitination and degradation of topoisomerase I and chromatin reorganization.

1 2D Structure

Lurtotecan

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(18S)-18-ethyl-18-hydroxy-2-[(4-methylpiperazin-1-yl)methyl]-6,9,20-trioxa-13,24-diazahexacyclo[12.11.0.03,12.05,10.015,24.017,22]pentacosa-1,3,5(10),11,13,15,17(22)-heptaene-19,23-dione

2.1.2 InChI

InChI=1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1

2.1.3 InChI Key

RVFGKBWWUQOIOU-NDEPHWFRSA-N

2.1.4 Canonical SMILES

CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OCCO6)CN7CCN(CC7)C)O

2.1.5 Isomeric SMILES

CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OCCO6)CN7CCN(CC7)C)O

2.2 Other Identifiers

2.2.1 UNII

4J1L80T08I

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(s)-camptothecin

2. Gg-211

3. Gg211

4. Gi 147211

5. Gi-147211

6. Gi147211

7. Gl 147211c

8. Gl-147211c

9. Gl147211c

10. Nx 211

11. Nx-211

12. Nx211 Cpd

13. Osi 211

14. Osi-211

15. Osi211

2.3.2 Depositor-Supplied Synonyms

1. 149882-10-0

2. Osi-211

3. Lurtotecan [inn]

4. 4j1l80t08i

5. Gg-211

6. Nx-211

7. Gi-147211

8. Gg 211; Gi 147211; Lurtotecan; Nx 211; Osi 211

9. Chembl341028

10. (s)-8-ethyl-8-hydroxy-15-((4-methylpiperazin-1-yl)methyl)-11,14-dihydro-2h-[1,4]dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12(3h,8h)-dione

11. Osi 211

12. Gg 211

13. Nx 211

14. Gi 147211

15. Unii-4j1l80t08i

16. Nx211 Cpd

17. Lurtotecan [who-dd]

18. Schembl19208

19. Chembl305666

20. Osi211

21. Dtxsid30164422

22. Gg211

23. Gl147211c

24. Gl 147211c

25. Bdbm50036130

26. Gw-211

27. Zinc22010625

28. Db12222

29. Gl-147211c

30. 11h-1,4-dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8h,14h)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8s)-

31. Gi147211

32. Hy-13670

33. Cs-0007547

34. A936765

35. Q6704977

36. D-myo-inositol2,4,5-trisphosphate,hexaammoniumsalt

37. 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(s)-camptothecin

38. (18s)-18-ethyl-18-hydroxy-2-[(4-methylpiperazin-1-yl)methyl]-6,9,20-trioxa-13,24-diazahexacyclo[12.11.0.03,12.05,10.015,24.017,22]pentacosa-1,3,5(10),11,13,15,17(22)-heptaene-19,23-dione

39. (8s)-8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-11h-p-dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8h,14h)-dione

40. (s)-8-ethyl-8-hydroxy-15-((4-methylpiperazin-1-yl)methyl)-2,3,11,14-tetrahydro-12h-[1,4]dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12(8h)-dione

41. 11h-1,4-dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8h,14h)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (s)

42. 8-ethyl-8-hydroxy-15-(4-methylhexahydro-1-pyrazinylmethyl)-(8s)-2,3,8,9,12,14-hexahydro-11h-[1,4]dioxino[2,3-g]pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-9,12-dione With Trifluoroaceticacid

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₃₀N₄O₆
Molecular Weight	518.6 g/mol
XLogP3	0.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	3
Exact Mass	518.21653469 g/mol
Monoisotopic Mass	518.21653469 g/mol
Topological Polar Surface Area	105 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	1070
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1